AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21318927 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face action planning intervention for diabetes patients
Number of subjects: 245
Study 21318927 — intervention group
Group type: EXPERIMENTAL
Intervention: Email-delivered intervention for active individuals
Number of subjects: 245
Study 19380853 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon‐alpha2a, 360 microg/wk for 12 weeks, then 180 microg/wk to complete 72 weeks (group A)
Number of subjects: 950
Study 19380853 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon‐alpha2a, 180 microg/wk for 48 weeks (group B)
Number of subjects: 950
Study 19380853 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon‐alpha2a, 180 microg/wk for 72 weeks (group C)
Number of subjects: 950
Study 19380853 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon‐alpha2a, 180 microg/wk for 48 weeks (group D)
Number of subjects: 950
Study 19380853 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended treatment duration (72 weeks vs 48 weeks)
Number of subjects: 950
Study 19380853 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete viral suppression at week 12 (groups A and B)
Number of subjects: 950
Study 19380853 — intervention group
Group type: COMPARATOR
Intervention: Complete viral suppression at week 12 (groups C and D)
Number of subjects: 950
Study 19380853 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete viral suppression at week 12
Number of subjects: 950
Study 17082468 — intervention group
Group type: EXPERIMENTAL
Intervention: 3APS 50 mg BID for 3 months
Number of subjects: 58
Study 17082468 — intervention group
Group type: EXPERIMENTAL
Intervention: 3APS 100 mg BID for 3 months
Number of subjects: 58
Study 17082468 — intervention group
Group type: EXPERIMENTAL
Intervention: 3APS 150 mg BID for 3 months
Number of subjects: 58
Study 17082468 — intervention group
Group type: EXPERIMENTAL
Intervention: 3APS 150 mg BID for 17 months (open-label phase)
Number of subjects: 58
Study 17082468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 15383193 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg 3 times daily)
Number of subjects: 94
Study 15383193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 11563808 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants told they would be able to smoke during the study
Number of subjects: 92
Study 11563808 — intervention group
Group type: COMPARATOR
Intervention: Participants told they would not be able to smoke
Number of subjects: 92
Study 11563808 — intervention group
Group type: COMPARATOR
Intervention: Participants told they might be able to smoke
Number of subjects: 92
Study 9762656 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) analysis including albumin CSF/PB ratio, MNC number, IgM, IgM index, C3, C4, NSE, S100, and lactate.
Number of subjects: 33
Study 9762656 — intervention group
Group type: COMPARATOR
Intervention: Cerebrospinal fluid (CSF) analysis
Number of subjects: 33
Study 8157579 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefminox 1 g
Number of subjects: 6
Study 8157579 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefminox 2 g
Number of subjects: 6
Study 8157579 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefminox 1 g and 2 g
Number of subjects: 6
Study 2969232 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g/d of oral thiamine hydrochloride for three months
Number of subjects: 11
Study 2969232 — intervention group
Group type: COMPARATOR
Intervention: Niacinamide placebo
Number of subjects: 11
Study 1695 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol (Blocadren)
Number of subjects: 10
Study 1695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31135821 — intervention group
Group type: EXPERIMENTAL
Intervention: Early dialysis initiation (estimated GFR >10.5 mL/min/1.73 m2)
Number of subjects: 28468
Study 31135821 — intervention group
Group type: COMPARATOR
Intervention: Acute inpatient dialysis initiations
Number of subjects: 28468
Study 31135821 — intervention group
Group type: COMPARATOR
Intervention: Home dialysis as the initial modality
Number of subjects: 28468
Study 31135821 — intervention group
Group type: COMPARATOR
Intervention: Arteriovenous access creation at hemodialysis initiation
Number of subjects: 28468
Study 29429598 — intervention group
Group type: EXPERIMENTAL
Intervention: Button-hole technique (group I, 44 patients)
Number of subjects: 87
Study 29429598 — intervention group
Group type: COMPARATOR
Intervention: Lowest part of the anterior suture line technique (group II, 43 patients)
Number of subjects: 87
Study 26792348 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 306
Study 26792348 — intervention group
Group type: COMPARATOR
Intervention: Control (saline injection)
Number of subjects: 306
Study 26792348 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (in high risk patients)
Number of subjects: 306
Study 24262719 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral educational intervention
Number of subjects: 540
Study 24262719 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (control)
Number of subjects: 540
Study 21771247 — intervention group
Group type: EXPERIMENTAL
Intervention: Systems-based post-prostatectomy models
Number of subjects: 373
Study 21771247 — intervention group
Group type: COMPARATOR
Intervention: D'Amico defined risk groups
Number of subjects: 373
Study 21771247 — intervention group
Group type: COMPARATOR
Intervention: Kattan 10-year postoperative nomogram
Number of subjects: 373
Study 21771247 — intervention group
Group type: COMPARATOR
Intervention: Surgical margin status
Number of subjects: 373
Study 21771247 — intervention group
Group type: COMPARATOR
Intervention: Extracapsular extension
Number of subjects: 373
Study 20452299 — intervention group
Group type: EXPERIMENTAL
Intervention: Music
Number of subjects: 109
Study 20452299 — intervention group
Group type: COMPARATOR
Intervention: Mute headphones (Control)
Number of subjects: 109
Study 17563874 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 40
Study 17563874 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 40
Study 15784985 — intervention group
Group type: EXPERIMENTAL
Intervention: Bread containing resistant starch (6 g of resistant starch derived from tapioca per 2 slices)
Number of subjects: 20
Study 15784985 — intervention group
Group type: COMPARATOR
Intervention: Placebo (bread not containing resistant starch)
Number of subjects: 20
Study 12403196 — intervention group
Group type: EXPERIMENTAL
Intervention: Priorix (MeMuRu)
Number of subjects: 0
Study 12403196 — intervention group
Group type: EXPERIMENTAL
Intervention: M-M-R II
Number of subjects: 0
Study 12403196 — intervention group
Group type: EXPERIMENTAL
Intervention: Triviraten
Number of subjects: 0
Study 12403196 — intervention group
Group type: EXPERIMENTAL
Intervention: Priorix + Varilrix (varicella vaccine)
Number of subjects: 0
Study 10717600 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue (MB) treated fresh frozen plasma (FFP)
Number of subjects: 12
Study 10717600 — intervention group
Group type: COMPARATOR
Intervention: Nontreated autologous fresh frozen plasma (FFP)
Number of subjects: 12
Study 7482430 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin III deficiency (< 70%)
Number of subjects: 40
Study 7482430 — intervention group
Group type: COMPARATOR
Intervention: Normal Antithrombin III levels (> 70%)
Number of subjects: 40
Study 2156706 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc DMSA renal scanning
Number of subjects: 32
Study 2156706 — intervention group
Group type: COMPARATOR
Intervention: Intravenous urography (IVU)
Number of subjects: 32
Study 7023672 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin alone (2 mg single dose)
Number of subjects: 48
Study 7023672 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (2 mg t.i.d.) for 3 days
Number of subjects: 48
Study 7023672 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (2 mg t.i.d.) + Oxprenolol (40 mg t.i.d.) for 3 days
Number of subjects: 48
Study 31256765 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 h placement budget
Number of subjects: 116
Study 31256765 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 h placement budget
Number of subjects: 116
Study 31256765 — intervention group
Group type: EXPERIMENTAL
Intervention: 55 h placement budget
Number of subjects: 116
Study 30815684 — intervention group
Group type: EXPERIMENTAL
Intervention: High CP (19%) diet
Number of subjects: 648
Study 30815684 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium CP (18%) diet
Number of subjects: 648
Study 30815684 — intervention group
Group type: COMPARATOR
Intervention: Low CP (17%) diet
Number of subjects: 648
Study 30815684 — intervention group
Group type: EXPERIMENTAL
Intervention: LMEMCP diet
Number of subjects: 648
Study 30815684 — intervention group
Group type: EXPERIMENTAL
Intervention: MME diet
Number of subjects: 648
Study 30815684 — intervention group
Group type: EXPERIMENTAL
Intervention: HCP diet
Number of subjects: 648
Study 30815684 — intervention group
Group type: EXPERIMENTAL
Intervention: MCP diet
Number of subjects: 648
Study 29116691 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO₂) at 2.2 bar for 90 minutes once a day, average number per patient: 4.7 sessions
Number of subjects: 49
Study 28316746 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape education for home instruction
Number of subjects: 80
Study 24795252 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium restriction (target sodium intake 50 mmol Na(+) per day)
Number of subjects: 45
Study 24795252 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (50 mg daily)
Number of subjects: 45
Study 24795252 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of sodium restriction and hydrochlorothiazide
Number of subjects: 45
Study 24795252 — intervention group
Group type: COMPARATOR
Intervention: Baseline treatment (no sodium restriction or hydrochlorothiazide)
Number of subjects: 45
Study 22176941 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine extended release (GXR) in the morning (GXR AM)
Number of subjects: 461
Study 22176941 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine extended release (GXR) in the evening (GXR PM)
Number of subjects: 461
Study 22176941 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus psychostimulant
Number of subjects: 461
Study 19749089 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy instruction
Number of subjects: 0
Study 19749089 — intervention group
Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 0
Study 19749089 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued conditions
Number of subjects: 0
Study 19749089 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial, gain (cued), and maintenance conditions
Number of subjects: 0
Study 19749089 — intervention group
Group type: EXPERIMENTAL
Intervention: Measures of WM capacity
Number of subjects: 0
Study 16988993 — intervention group
Group type: EXPERIMENTAL
Intervention: Real exposure with neutral information (group expo)
Number of subjects: 74
Study 16988993 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham exposure with positive information (group+)
Number of subjects: 74
Study 16988993 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham exposure with negative information (group‐)
Number of subjects: 74
Study 16988993 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham exposure with neutral information (group+/‐)
Number of subjects: 74
Study 16988993 — intervention group
Group type: COMPARATOR
Intervention: Control group (not exposed, no field-related information)
Number of subjects: 74
Study 16039210 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass grafting
Number of subjects: 31
Study 16039210 — intervention group
Group type: COMPARATOR
Intervention: On-pump coronary artery bypass grafting
Number of subjects: 31
Study 16039210 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 31
Study 12015434 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pre-exercise muscle glycogen (240 +/- 38 mmol kg(‐1) dry weight)
Number of subjects: 6
Study 12015434 — intervention group
Group type: COMPARATOR
Intervention: Control pre-exercise muscle glycogen (398 +/- 52 mmol kg(‐1) dry weight)
Number of subjects: 6
Study 9828867 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy with essential oils (thyme, rosemary, lavender, and cedarwood) mixed with carrier oils (jojoba and grapeseed) applied daily.
Number of subjects: 86
Study 9828867 — intervention group
Group type: COMPARATOR
Intervention: Carrier oils (jojoba and grapeseed) applied daily (Control group).
Number of subjects: 86
Study 7924285 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulation wools (5 types: 2 rockwool, 3 glasswool)
Number of subjects: 0
Study 7924285 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulation wools with the smallest diameter
Number of subjects: 0
Study 7924285 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulation wools with the largest diameter
Number of subjects: 0
Study 7924285 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of 'shot' in rockwool
Number of subjects: 0
Study 7924285 — intervention group
Group type: COMPARATOR
Intervention: Control test site (no insulation wools)
Number of subjects: 0
Study 2668980 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolipram
Number of subjects: 64
Study 2668980 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 64
Study 371644 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral verapamil 480 mg/day
Number of subjects: 12
Study 371644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31884854 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 50 mg, 150 mg, 300 mg
Number of subjects: 10061
Study 31884854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10061
Study 31124588 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunoglobulin supplementation (20 g in milk twice daily for 14 days)
Number of subjects: 102
Study 31124588 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 g of a product with similar nutritional value but without immunoglobulins in milk, twice daily for 14 days)
Number of subjects: 102
Study 31124588 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplements)
Number of subjects: 102
Study 28086991 — intervention group
Group type: EXPERIMENTAL
Intervention: Water aerosol exposure for 1 hour/day (n=33)
Number of subjects: 65
Study 28086991 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=26)
Number of subjects: 65
Study 28086991 — intervention group
Group type: EXPERIMENTAL
Intervention: Distant site exposure for 1 hour/day (n=32)
Number of subjects: 65
Study 26004166 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich breakfast (1963 kJ)
Number of subjects: 35
Study 26004166 — intervention group
Group type: COMPARATOR
Intervention: Extended morning fasting
Number of subjects: 35
Study 26004166 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich breakfast
Number of subjects: 35
Study 23301502 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir (2.5 mg/kg intravenously)
Number of subjects: 6
Study 23301502 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir (1800 mg orally)
Number of subjects: 6
Study 21479654 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (low-CHO; 20% CHO, 40% protein, 40% fat)
Number of subjects: 10
Study 21479654 — intervention group
Group type: COMPARATOR
Intervention: Moderate-carbohydrate diet (mod-CHO; 55% CHO, 15% protein, 30% fat)
Number of subjects: 10
Study 21479654 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (low-CHO)
Number of subjects: 10
Study 21479654 — intervention group
Group type: COMPARATOR
Intervention: Moderate-carbohydrate diet (mod-CHO)
Number of subjects: 10
Study 19339324 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery Workbook training in addition to usual treatment (N=16)
Number of subjects: 33
Study 19339324 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (Control group, N=17)
Number of subjects: 33
Study 19455856 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing about deepest thoughts regarding the exam
Number of subjects: 0
Study 19455856 — intervention group
Group type: COMPARATOR
Intervention: Neutral and nonemotional topics writing (Control)
Number of subjects: 0
Study 16120031 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold forearm
Number of subjects: 19
Study 16120031 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm forearm
Number of subjects: 19
Study 16120031 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold fingertip
Number of subjects: 19
Study 12083533 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP+CHX (scaling and root planing plus chlorhexidine chip)
Number of subjects: 20
Study 12083533 — intervention group
Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 20
Study 12083533 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP+CHX
Number of subjects: 20
Study 9725552 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily
Number of subjects: 20
Study 9725552 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine alone
Number of subjects: 20
Study 9725552 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine with atorvastatin
Number of subjects: 20
Study 7651649 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin-sulbactam
Number of subjects: 53
Study 7651649 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 53
Study 2528256 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% azelaic acid cream
Number of subjects: 0
Study 355024 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intramuscular injections)
Number of subjects: 4
Study 355024 — intervention group
Group type: COMPARATOR
Intervention: Placebo (tablets)
Number of subjects: 4
Study 355024 — intervention group
Group type: EXPERIMENTAL
Intervention: No treatment (untreated patients)
Number of subjects: 4
Study 11369067 — intervention group
Group type: COMPARATOR
Intervention: Conventional computed tomography-based treatment planning (Group A, n=11)
Number of subjects: 23
Study 11369067 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual simulation (Group B, n=12)
Number of subjects: 23
Study 30519531 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-supported internet-based cognitive behavioural therapy (ICBT)
Number of subjects: 71
Study 30519531 — intervention group
Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 71
Study 28827103 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg per day
Number of subjects: 0
Study 28827103 — intervention group
Group type: COMPARATOR
Intervention: Bicalutamide 50 mg per day
Number of subjects: 0
Study 27436788 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin
Number of subjects: 262
Study 27436788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262
Study 25275271 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 9340
Study 25275271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9340
Study 22016505 — intervention group
Group type: EXPERIMENTAL
Intervention: Galectin-3 levels
Number of subjects: 895
Study 20513067 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive cardiovascular risk factor intervention
Number of subjects: 104
Study 17673568 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (T) + Resistance training (R)
Number of subjects: 0
Study 17673568 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P) + Resistance training (R)
Number of subjects: 0
Study 17673568 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (T) + No Resistance training (R)
Number of subjects: 0
Study 17673568 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P) + No Resistance training (R)
Number of subjects: 0
Study 15610950 — intervention group
Group type: EXPERIMENTAL
Intervention: ziprasidone (80-120 mg/day)
Number of subjects: 20
Study 15610950 — intervention group
Group type: COMPARATOR
Intervention: haloperidol (5-20 mg/day)
Number of subjects: 20
Study 15610950 — intervention group
Group type: EXPERIMENTAL
Intervention: ziprasidone
Number of subjects: 20
Study 15610950 — intervention group
Group type: COMPARATOR
Intervention: haloperidol
Number of subjects: 20
Study 12378660 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion 3-6 mg kg‐1 h‐1
Number of subjects: 24
Study 12378660 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl infusion 10-30 micrograms kg‐1 h‐1
Number of subjects: 24
Study 10210379 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose of epirubicin (1 mg/ml, 50 mg/50 ml solution)
Number of subjects: 122
Study 10210379 — intervention group
Group type: COMPARATOR
Intervention: High dose of epirubicin (2 mg/ml, 100 mg/50 ml solution)
Number of subjects: 122
Study 7616867 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy flour (n = 28)
Number of subjects: 58
Study 7616867 — intervention group
Group type: COMPARATOR
Intervention: Wheat flour (n = 30)
Number of subjects: 58
Study 2702064 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral intake of 6-mercaptopurine (6-MP) in fasting state
Number of subjects: 10
Study 2702064 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral intake of 6-mercaptopurine (6-MP) with breakfast
Number of subjects: 10
Study 2702064 — intervention group
Group type: COMPARATOR
Intervention: Comparison of fasting state vs. breakfast intake of 6-MP
Number of subjects: 10
Study 178197 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of glucagon
Number of subjects: 12
Study 178197 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of propantheline bromide
Number of subjects: 12
Study 178197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31774299 — intervention group
Group type: EXPERIMENTAL
Intervention: HELP diet with 400 mg/kg Res
Number of subjects: 144
Study 31774299 — intervention group
Group type: COMPARATOR
Intervention: HELP diet
Number of subjects: 144
Study 31774299 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard diet with 400 mg/kg Res
Number of subjects: 144
Study 31774299 — intervention group
Group type: COMPARATOR
Intervention: Standard diet
Number of subjects: 144
Study 29906719 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral activation (BA)
Number of subjects: 78